AbbVie Inc.

ABBVNYSE

$284.60

Last price · USD

Multiples use last price and FY2025 annual figures. Market cap estimated from diluted shares.

AbbVie Inc. income statement

Annual · USD millions except per-share data · 26 lines

Fiscal year	2025latest	2024	2023	2022	2021	CAGR
Revenue & gross profit
Revenue	61,160	56,334	54,318	58,054	56,197	+2.1%
Cost of revenue	18,204	16,904	20,415	17,414	17,446	+1.1%
Gross profit	42,956	39,430	33,903	40,640	38,751	+2.6%
Operating expenses & income
Research & development	9,096	12,791	7,675	6,510	8,046	+3.1%
SG&A (combined)	14,010	14,752	12,872	15,260	12,349	+3.2%
Total operating expenses	22,865	30,293	21,146	22,523	20,827	+2.4%
Cost and expenses	41,069	47,197	41,561	39,937	38,273	+1.8%
Operating income	20,091	9,137	12,757	18,117	17,924	+2.9%
Non-operating & other
Interest income	266	648	540	186	39	+61.6%
Interest expense	2,893	2,808	2,224	2,230	2,423	+4.5%
Net interest income	(2,627)	(2,160)	(1,684)	(2,044)	(2,384)	—
Non-operating income (excl. interest)	10,601	2,613	4,283	2,410	2,512	+43.3%
Other expenses	(241)	2,750	599	753	432	—
Total other income (expenses), net	(13,494)	(5,421)	(6,507)	(4,640)	(4,935)	—
Profitability
Depreciation & amortization	8,139	8,386	8,698	8,467	8,521	-1.1%
Income before tax	6,597	3,716	6,250	13,477	12,989	-15.6%
Income tax expense	2,364	(570)	1,377	1,632	1,440	+13.2%
Net income from continuing operations	4,233	4,286	4,873	11,845	11,549	-22.2%
Net income	4,226	4,278	4,863	11,836	11,542	-22.2%
Bottom line net income	4,196	4,238	4,820	11,782	11,468	-22.2%
Additional fields
Ebit	9,490	6,524	8,474	15,707	15,412	-11.4%
Ebitda	17,629	14,910	17,172	24,174	23,933	-7.4%
Eps	$2.37	$2.40	$2.73	$6.65	$6.48	-22.2%
Eps Diluted	$2.37	$2.39	$2.72	$6.63	$6.45	-22.1%
Weighted Average Shs Out	1,774	1,769	1,768	1,771	1,770	+0.1%
Weighted Average Shs Out Dil	1,774	1,773	1,773	1,778	1,777	0.0%